Law firm Bragar Eagel & Squire is investigating Alnylam Pharmaceuticals for potential federal securities law violations following the company's July 30, 2026 announcement of a $200 million reduction in TTR product sales guidance. The guidance cut, attributed to normalization of growth after initial market launch, triggered a 28.35% intraday stock price decline. The firm is seeking stockholders who suffered losses to participate in potential litigation.

The Law Offices of Frank R. Cruz is investigating Alnylam Pharmaceuticals for possible federal securities law violations. On July 30, 2026, Alnylam lowered its TTR product sales guidance by approximately $200 million due to slower-than-expected growth in the ATTR-CM market after initial pent-up demand was satisfied. The announcement triggered a 28.35% intraday stock decline, causing investor losses.

Law firm Kirby McInerney LLP is investigating potential securities fraud claims against Alnylam Pharmaceuticals following the company's announcement on July 30, 2026, that it lowered TTR product sales guidance by approximately $200 million due to normalization of growth in the ATTR-CM market after satisfying pent-up demand. The stock fell 28% ($81.14 per share) to $205.48 on the news.

Atlas Healthcare Fund, managed by VST Capital, showcased its track record of early conviction investments in healthcare, with notable positions in Eli Lilly (entered at $350, now trading above $1,200), Alnylam Pharmaceuticals, TransMedics Group, and Inari Medical. The fund has delivered cumulative net returns of +1,720.9% since inception in January 2020, averaging over 57% annually, by identifying clinically differentiated technologies before mainstream market recognition.

The global oligonucleotide contract development and manufacturing organization (CDMO) market is experiencing strong growth driven by expanding RNA-targeted medicine pipelines, increased outsourcing of complex synthesis and manufacturing, and rising demand for precision medicine. The market is projected to grow at a 21.81% CAGR through 2031, with contract manufacturing leading at 51.68% market share in 2025. Antisense oligonucleotides dominate at 58.23% revenue, while siRNA is the fastest-growing segment at 23.25% CAGR. Asia-Pacific is the fastest-growing region at 24.56% CAGR, driven by capacity expansion in China, South Korea, and Japan.

The transthyretin amyloidosis treatment market is projected to grow from USD 8.95 billion in 2025 to USD 35.10 billion by 2035 at a 14.64% CAGR. Growth is driven by increased ATTR-CM diagnosis rates, FDA approvals of gene-silencing therapies like vutrisiran and acoramidis, improved diagnostic imaging, and expanding pipeline therapies. North America dominates with 46% market share, while Asia Pacific is the fastest-growing region.

Alnylam Pharmaceuticals has gained strong analyst support with 21 of 29 analysts rating it as buy or strong buy, with an average price target of $436 (45% upside). The company is transitioning from a clinical biotech to a profitable commercial powerhouse, with Q1 product revenue surging 121% year-over-year to $1.04 billion, driven by its ATTR franchise. The company's pipeline is expanding into mainstream markets like cardiomyopathy and hypertension, supported by a unique RNAi delivery platform that creates a competitive moat. However, the stock trades at a high valuation of 75x trailing earnings, with risks from competitive pricing pressure.

The global protein synthesis research market is experiencing accelerating growth driven by increased investment in cell and gene therapy research, rising chronic disease prevalence, and expanding healthcare budgets. North America leads with 42.8% market share, while Asia-Pacific infrastructure expansion presents significant growth opportunities. Key market drivers include strong late-stage therapy pipelines and government support through initiatives like the CHIPS and Science Act.

The oligonucleotides clinical trial landscape is expanding rapidly with 200+ companies developing 600+ pipeline drugs. Major players like Novartis, Alnylam Pharmaceuticals, Amgen, and WaVe Life Sciences are advancing promising therapies across various clinical stages. Approximately 20+ oligonucleotides are in late-stage development while 150+ are in mid and early stages. Recent developments include SanegeneBio's $110M Series B funding, FDA approvals for multiple orphan drug designations, and several companies advancing Phase II and Phase III trials.

Edgewise Therapeutics, a $3.1B biotech company, has two major drug candidates with significant market potential. EDG-7500 for hypertrophic cardiomyopathy uses a novel mechanism (promoting heart relaxation) with superior safety profile compared to existing treatments, with efficacy data expected by June 2026. Sevasemten targets Becker Muscular Dystrophy, a disease with zero approved treatments, with pivotal trial results expected Q4 2026. The stock has tripled from its 52-week low and faces two binary catalysts this year.

BridgeBio Pharma stock surged 12.60% following William Blair's initiation of coverage with an Outperform rating and $93.03 price target. The analyst highlighted the company's accelerating Attruby launch, near-term NDA submissions for disease-modifying therapies, and a strong pipeline in rare genetic diseases including achondroplasia and autosomal dominant hypocalcemia. BridgeBio's products are positioned as next-generation alternatives to Pfizer's market-leading tafamidis.

Tenaya Therapeutics shares surged 31.20% following a research collaboration agreement with Alnylam Pharmaceuticals focused on discovering genetic targets for cardiovascular disease treatments. Tenaya will validate up to 15 gene targets and receive up to $10 million in upfront payments with potential milestone payments reaching $1.13 billion. Despite the positive news, the stock remains in a bearish trend trading below its 100-day and 200-day moving averages.